Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
February 13th 2024Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.
Read More
Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
February 13th 2024Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.
Read More
Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL
July 28th 2022Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
Read More